Skip to content

13F-HR filed by 5AM Venture Management, LLC

5AM Venture Management, LLC filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 31 holding rows worth $419,052,435.

Accession
0001085146-25-001687
Filed
2025-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2024

A holdings report, 31 entries on the cover page, a total value of $419,052,435 stated on the cover page (in dollars after the unit check, H1), rows summing to $419,052,435 with VALUE read as dollars as filed, 13F file number 028-19757. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ENTRADA THERAPEUTICS INC COM29384C108Stock4,408,379$76,220,873dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock1,629,765$36,669,713dollars as filed
SKYE BIOSCIENCE INC83086J200COM NEW9,913,168$28,054,265dollars as filed
TECTONIC THERAPEUTIC INC878972108COMMON STOCK596,660$27,547,792dollars as filed
ARTIVA BIOTHERAPEUTICS INC04317A107COM2,353,304$23,721,304dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM1,027,711$22,404,100dollars as filed
BIOHAVEN LTDG1110E107COM478,972$17,889,604dollars as filed
PHARVARIS NVN69605108COMMON STOCK797,600$15,289,992dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock282,313$15,287,249dollars as filed
CAMP4 THERAPEUTICS CORP13463J101COM2,927,915$15,283,716dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM736,595$14,120,526dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS830,945$13,918,329dollars as filed
ERASCA INC COM29479A108Stock5,405,404$13,567,564dollars as filed
PRAXIS PRECISION MEDICINES I74006W207COM NEW170,000$13,083,200dollars as filed
TYRA BIOSCIENCES INC90240B106COMMON STOCK939,298$13,056,242dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW497,270$12,566,013dollars as filed
EYEPOINT INC COM NEW30233G209Stock1,050,000$7,822,500dollars as filed
VIKING THERAPEUTICS INC92686J106COM189,593$7,629,222dollars as filed
VOR BIOPHARMA INC929033108COM6,361,723$7,061,513dollars as filed
ANAPTYSBIO INC032724106COM357,733$4,736,385dollars as filed
AKERO THERAPEUTICS INC00973Y108COM165,000$4,590,300dollars as filed
SCPHARMACEUTICALS INC810648105COM1,200,647$4,250,290dollars as filed
PROTARA THERAPEUTICS INC74365U107COM STK800,000$4,224,000dollars as filed
GH RESEARCH PLC ORDINARY SHARESG3855L106Stock572,665$4,008,655dollars as filed
RALLYBIO CORP75120L100COM3,630,724$3,485,495dollars as filed
SILENCE THERAPEUTICS PLC82686Q101ADS476,200$3,276,256dollars as filed
ADVERUM BIOTECHNOLOGIES INC00773U207COM NEW541,666$2,529,580dollars as filed
ALECTOR INC014442107COMMON STOCK995,841$1,882,139dollars as filed
Mersana Therapeutics Inc59045L106Common Stock1,305,000$1,866,150dollars as filed
CIDARA THERAPEUTICS INC171757206COM NEW56,725$1,524,768dollars as filed
ZENTALIS PHARMACEUTICALS INC98943L107COMMON STOCK490,000$1,484,700dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001085146-25-001687this filing2025-02-14acceptance time not in the bulk data set